Among mammals, only man and dog are known to develop syrnptoms of nicotinic acid deficiency. In man, deficiency results in dermatitis, diarrhea, delirium, and death. Recently, nicotinic acid has been found to lower serum cholesterol levels in hypercholesteremic and normal persons (1) and to diminish atheromatous plaques in rabbits (2) . Because of the renewed clinical interest in nicotinic acid, a more specific and sensitive assay for nicotinic acid than those described (3-6) is warranted. can be added at 0.3, 1.0, 3.0, 10, 100, and 300 mg./ml. final concentrations in the assay medium.
METHODS

The organism used is Tetrahymena pyriformis
Solutions are kept at 4#{176} with added volatile preservative (12); a control flask consisting of basal medium alone is maintained to allow estimation of carry-over error owing to the nicotinic activity of the maintenance medium. For inoculum, 5 ml. of a 24-hr. culture, prepared as described (7) , are diluted with 10 ml.
of full-strength basal medium. The flasks are inoculated with 1 drop of this suspension and incubated at 28-30#{176} for 3 days. Additional technical details have been described (7, 12, 13) .
RESULTS
Responses of T. pyriformis
to nicotinic acid and its various derivatives are given in Table 2 . The range of nicotinic acid activity (Table  3) in blood, serum, and urine for a group of 28 normal subjects is 2.7-9.6 g./ml.
Only a fraction of less than 1 per cent (0.016-0.05 g./ ml.) of this quantity was present in serum. The range in urine was 1.16-1.54 pg./ml.
Ninety-seven to 101, per cent of added combinations of nicotinic acid and nicotinamide was recovered when added to blood Table 3 ). Such results are expected since red blood cells contain much DPN and TPN activity (7) (8) (9) . Among the excretory products of nicotinic acid in human urine is nicotinuric acid (nicotinyiglycine). 
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